Donepezil for vascular cognitive impairment.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2004-01-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD004395.PUB2PMID 14974068PMCID PMC12597227
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular cognitive impairment

  2005cited by this paper
• Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias

  2005cited by this paper
• Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia

  2005cited by this paper
• P3-402 Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits

  2004cited by this paper
• The nucleus basalis of Meynert in multi-infarct (vascular) dementia

  2004cited by this paper
• P3-403 Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities

  2004cited by this paper
• Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial

  2003cited by this paper
• Donepezil in vascular dementia

  2003cited by this paper
• August 26 Highlights

  2003cited by this paper
• Donepezil‐Treated Patients with Probable Vascular Dementia Demonstrate Cognitive Benefits

  2002cited by this paper
• The surgical management of spasticity.

  2002cited by this paper
• Therapeutical considerations in patients with intracranial venous angiomas

  2002cited by this paper
• Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia.

  2002cited by this paper
• Donepezil Treatment of Vascular Dementia

  2002cited by this paper
• Vascular cognitive impairment.

  2002cited by this paper
• Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales

  2001cited by this paper
• Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

  2001cited by this paper
• A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

  2001cited by this paper
• Drugs for Alzheimer's disease

  2001cited by this paper
• Donepezil (Aricept®) treatment of multi infarct dementia: The caregivers and clinical impression

  2000cited by this paper
• Cholinergic dysfunction in diseases with Lewy bodies

  2000cited by this paper
• Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.

  1999cited by this paper
• Type 2 diabetes mellitus, cognitive impairment and dementia

  1999cited by this paper
• Cerebral infarcts in patients with autopsy-proven Alzheimer's disease

  1998cited by this paper
• Mechanism of nicotine-induced relaxation in the porcine basilar artery.

  1998cited by this paper
• Presence and treatment of vascular risk factors in patients with vascular cognitive impairment.

  1997cited by this paper
• Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.

  1997cited by this paper
• Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

  1997cited by this paper
• Epidemiology of vascular dementia.

  1995cited by this paper
• Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging.

  1995cited by this paper
• Prospective CT confirms differences between vascular and Alzheimer's dementia.

  1995cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology Confirmation of the Clinical Diagnosis of Alzheimer's Disease

  1995cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• How does cerebrovascular disease cause dementia?

  1994cited by this paper
• The neurochemistry of vascular dementia.

  1994cited by this paper
• Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort.

  1993cited by this paper
• Vascular dementia

  1993cited by this paper
• Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

  1992cited by this paper
• Prevalence and Etiology of Dementia in a Japanese Community

  1992cited by this paper
• Preventable senility: a call for action against the vascular dementias.

  1992cited by this paper
• The Prevalence of Dementia in Europe: A Collaborative Study of 1980–1990 Findings

  1991cited by this paper
• The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group.

  1991cited by this paper
• The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education

  1990cited by this paper
• Vascular dementia: too much, or too little?

  1988cited by this paper
• Clinical Dementia Rating (CDR).

  1988cited by this paper
• Vascular dementia is overdiagnosed.

  1988cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

  1977cited by this paper
• Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

  1976cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• An analysis of the learning deficit following hyoscine administration to man

  1973cited by this paper

• Clinical practice guidelines on addressing cognitive impairment in vascular dementias

  2025cites this paper
• Creatine and Taurine as Novel Competitive Inhibitors of Acetylcholinesterase: A Biochemical Basis for Nutritional Modulation of Brain Function

  2025cites this paper
• Principaux troubles neurocognitifs non liés à une maladie d’Alzheimer

  2024cites this paper
• Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches

  2024cites this paper
• [Experience of using the combined drug Mioreol in patients with Alzheimer's disease and mixed dementia].

  2024cites this paper
• Incident Dementia After Spontaneous Intracerebral Hemorrhage

  2024cites this paper
• Discriminant Potential of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in Greek Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment

  2024cites this paper
• Efficacy of acetylcholinesterase inhibitors for cognitive impairment in multiple sclerosis: A systematic review and meta-analysis

  2024cites this paper
• Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)

  2024cites this paper
• Vascular dementia subtypes, pathophysiology, genetics, neuroimaging, biomarkers, and treatment updates along with its association with Alzheimer's dementia and diabetes mellitus.

  2023cites this paper
• Novel Benzothiazole Sulfonamides as Potent α-Glucosidase and Cholinesterase Inhibitors: Design, Synthesis, Structural Properties, Biological Evaluation and Docking Studies

  2023cites this paper
• Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease

  2022cites this paper
• Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based on dosage in patients with vascular cognitive impairment: a network meta-analysis.

  2022cites this paper
• The efficacy of pharmacological interventions to improve cognitive and behavior symptoms in people with dementia: A systematic review and meta‐analysis

  2022cites this paper
• Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis

  2022cites this paper
• Nootropic effect of Syzygium polyanthum (Wight) Walp leaf extract in chronic cerebral hypoperfusion rat model via cholinergic restoration: a potential therapeutic agent for dementia

  2022cites this paper
• Association of Cerebral Small Vessel Disease With Gait and Balance Disorders

  2022cites this paper
• 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

  2022cites this paper
• Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia

  2022cites this paper
• A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan

  2021cites this paper
• THE EFFECT OF DURATION OF ACETYLCHOLINE-ESTERASE INHIBITOR ON MMSE, CDT AND BARTHEL INDEX SCORING ON PATIENTS WITH VASCULAR DEMENSIA

  2021cites this paper
• A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Issues Regarding Post-Stroke Complications in Japan.

  2021cites this paper
• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.

  2021cites this paper
• Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment

  2021cites this paper
• Impact of an Education Program for Caregivers of Patients with Alzheimer's Disease on Treatment Discontinuation and Compliance in Korea

  2021cites this paper
• Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions

  2021cites this paper
• Synthesis, structural properties and potent bioactivities supported by molecular docking and DFT studies of new hydrazones derived from 5-chloroisatin and 2-thiophenecarboxaldehyde

  2021cites this paper
• Anti-dementia Medication

  2021cites this paper
• Cholinesterase inhibitors in dementias

  2020cites this paper
• Effect of acupuncture treatment on post-stroke cognitive impairment

  2020cites this paper
• What are the diagnostic criteria for vascular dementia (VaD)?

  2020cites this paper
• Dementia

  2020cites this paper
• Pharmacological Treatment of Post-stroke Cognitive Deficits

  2020cites this paper
• Pharmacotherapy of non-Alzheimer's types of dementia

  2020cites this paper
• Farmakoterapie nealzheimerovských typů demencí

  2020cites this paper
• Effect of Donepezil on Cognitive Disorders Due to the Selective Serotonin Reuptake Inhibitors in the Patients with Major Depressive Disorder

  2020cites this paper
• Prevention and Management of Acute and Late Toxicities in Radiation Oncology: Management of Toxicities in Radiation Oncology

  2020cites this paper
• Cochrane Database of Systematic Reviews Addenbrooke’s Cognitive Examination III (ACE-III) andmini- ACE for the detection of dementia andmild cognitive impairment (Protocol)

  2019cites this paper
• Addenbrooke's Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment.

  2019cites this paper
• Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis

  2019influential citation
• Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia.

  2019cites this paper
• Serum Level and Activity of Butylcholinesterase: A Biomarker for Post-Stroke Dementia

  2019cites this paper
• Démence

  2019cites this paper
• PGPM_A_211259 209..224

  2019cites this paper
• The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches.

  2019cites this paper
• Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia

  2019cites this paper
• Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes

  2019influential citation
• Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

  2019cites this paper
• Cochrane Database of Systematic Reviews Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis (Protocol)

  2019cites this paper
• Acetylcholinesterase inhibitors from southern African plants: An overview of ethnobotanical, pharmacological potential and phytochemical research including and beyond Alzheimer's disease treatment

  2019cites this paper
• Glycogen synthase kinase-3 inhibition as a potential pharmacological target for vascular dementia: In silico and in vivo evidence

  2019cites this paper
• Stepwise occlusion of the carotid arteries of the rat: MRI assessment of the effect of donepezil and hypoperfusion-induced brain atrophy and white matter microstructural changes

  2018cites this paper
• Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.

  2018cites this paper
• Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults

  2018cites this paper
• Cerebral Perfusion Insufficiency and Relationships with Cognitive Deficits in Alzheimer’s Disease: A Multiparametric Neuroimaging Study

  2018cites this paper
• The Black Book of Psychotropic Dosing and Monitoring.

  2018cites this paper
• Prevencija, prepoznavanje i prognoza vaskularnog kognitivnog poremećaja

  2018cites this paper
• Effect of chongmyungtang, a traditional Korean polyherbal formula, on the Pharmacokinetic profiles of donepezil in rats.

  2017cites this paper
• Concern about developing Alzheimer's disease or dementia and intention to be screened: An analysis of national survey data.

  2017cites this paper
• Different pharmacological responses in late‐life depression with subsequent dementia: a case supporting the reserve threshold theory

  2017cites this paper
• Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment

  2017cites this paper
• Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

  2017cites this paper
• Cholinergic symptoms and QTc prolongation following donepezil overdose.

  2017cites this paper
• Twelve tips for assessing and managing mild cognitive impairment and major neurocognitive disorder in older people Twelve practical and evidence-informed recommendations can help in the delivery of dementia care

  2017cites this paper
• Choto‐san versus placebo for patients with dementia: systematic review and meta‐analysis

  2017cites this paper
• Vascular cognitive impairment and vascular dementia

  2017cites this paper
• Geriatric Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Depression, Dementia, and Dementia-Related Disorders in the Elderly

  2017cites this paper
• A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy

  2016cites this paper
• Clinical practice guidelines for dementia in Australia

  2016cites this paper
• Clinical practice guidelines and principles of care for people with dementia in Australia.

  2016cites this paper
• Vascular cognitive impairment, a cardiovascular complication.

  2016cites this paper
• Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia.

  2016cites this paper
• Neurodegenerative and Vascular Involvement in Post Stroke Dementia

  2016cites this paper
• Clinical Practice Guidelines for Dementia in Australia: A step towards improving uptake of research findings in health‐ and aged‐care settings

  2016cites this paper
• Management of dementia: review of evidence

  2016cites this paper
• A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol

  2016cites this paper
• PHARMACOLOGICAL COGNITIVE ENHANCERS IN NEUROPSYCHIATRY-A CRITICAL APPRAISAL

  2015cites this paper
• Potentially Suboptimal Prescribing for Older Veteran Nursing Home Patients With Dementia

  2015cites this paper
• Evaluation and management of the elderly patient presenting with cognitive complaints.

  2015cites this paper
• Post-Stroke Cognitive Impairment

  2015cites this paper
• Cognition enhancers for the treatment of dementia

  2015cites this paper
• Poststroke cognitive impairment and dementia: prevalence, diagnosis, and treatment

  2014cites this paper
• Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating

  2014cites this paper
• Morphology‐based mammalian stem cell tests reveal potential developmental toxicity of donepezil

  2014cites this paper
• Poststroke cognitive impairment and dementia: prevalence, diagnosis, and treatment

  2014cites this paper
• Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia.

  2014cites this paper
• Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease

  2014cites this paper
• Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease

  2014cites this paper
• Independent assessment of improvements in dementia care and support since 2009

  2014cites this paper
• Meðferðarúrræði við Alzheimerssjúkdómnum : lyf og lyfleysur

  2014cites this paper
• Molecular Mechanics Steric Energy Evaluation of Reversible Acetyl cholinesterase Inhibitor, Donepezil, (RS)-2-([1-benzyl-4-piperidyl] methyl)-5,6-dimethoxy-2,3-dihydroinden-1-one

  2014cites this paper
• Screening for Cognitive Impairment in a Stroke Prevention Clinic Using the MoCA

  2013cites this paper
• Initiation of Cholinesterase Inhibitors in an Inpatient Setting

  2013cites this paper
• Association Healthcare Professionals From the American Heart Association/American Stroke Vascular Contributions to Cognitive Impairment and Dementia : A Statement for

  2013cites this paper
• Vascular Cognitive Impairment

  2013cites this paper
• Chapter 11 – TIAs and Strokes

  2013cites this paper
• Rivastigmine for vascular cognitive impairment.

  2013cites this paper
• Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews

  2013cites this paper
• Chapter 7 – Dementia

  2013cites this paper
• Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1.

  2013cites this paper